Your browser doesn't support javascript.
loading
Escitalopram and progressive muscle relaxation training are both effective for the treatment of hot flashes in patients with breast cancer: a randomized controlled trial.
Shirzadi, Maryam; Farshchian, Negin; Nazarpour, Arash; Eskandari, Soudabeh; Kahrari, Fahimeh; Abdollahpour Ranjbar, Hamed; Nazari, Somayeh; Hekmati, Issa; Farhang, Sara.
Afiliación
  • Shirzadi M; Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Farshchian N; Department of Radiation Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Nazarpour A; Department of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Eskandari S; Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Kahrari F; Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Abdollahpour Ranjbar H; Koc University College of Social Sciences and Humanities, Istanbul, Turkey.
  • Nazari S; Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Hekmati I; University of Maragheh, East Azerbaijan, Iran.
  • Farhang S; Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, East Azerbaijan, Iran.
J Psychosom Obstet Gynaecol ; 43(4): 393-399, 2022 12.
Article en En | MEDLINE | ID: mdl-34647858
ABSTRACT

INTRODUCTION:

Available treatments for hot flashes in patients with breast cancer are not always tolerable or effective for all patients.

METHODS:

Patients diagnosed to have primary breast cancer were randomly allocated to receive 10 mg of escitalopram, placebo, or progressive muscle relaxation therapy. Patients were asked to report the frequency and duration of hot flashes during day and night, at baseline and after ten weeks of treatment, and completed the menopause rating scale.

RESULTS:

Eighty-two patients were randomly assigned to receive escitalopram (n = 26), PMRT (n = 28), and placebo (n = 28). PMRT and escitalopram could effectively decrease number and duration of diurnal and nocturnal HFs in patients with breast cancer, with a better effect observed from escitalopram. They could both decrease the total score of MRS.

CONCLUSION:

Both escitalopram ad PMRT can reveal nocturnal and diurnal HFs in terms of frequency and duration in patients with breast cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Sofocos Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: J Psychosom Obstet Gynaecol Año: 2022 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Sofocos Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: J Psychosom Obstet Gynaecol Año: 2022 Tipo del documento: Article País de afiliación: Irán